These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 21639875)

  • 1. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study.
    Allin KH; Nordestgaard BG; Flyger H; Bojesen SE
    Breast Cancer Res; 2011 Jun; 13(3):R55. PubMed ID: 21639875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients.
    Pierce BL; Ballard-Barbash R; Bernstein L; Baumgartner RN; Neuhouser ML; Wener MH; Baumgartner KB; Gilliland FD; Sorensen BE; McTiernan A; Ulrich CM
    J Clin Oncol; 2009 Jul; 27(21):3437-44. PubMed ID: 19470939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival.
    Frydenberg H; Thune I; Lofterød T; Mortensen ES; Eggen AE; Risberg T; Wist EA; Flote VG; Furberg AS; Wilsgaard T; Akslen LA; McTiernan A
    Breast Cancer Res Treat; 2016 Jan; 155(2):345-54. PubMed ID: 26740213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer.
    Andersen HH; Bojesen SE; Johansen JS; Ejlertsen B; Berg T; Tuxen M; Madsen K; Danø H; Flyger H; Jensen MB; Nielsen DL
    Cancer Epidemiol Biomarkers Prev; 2024 May; 33(5):662-670. PubMed ID: 38358318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating C-reactive protein levels as a prognostic biomarker in breast cancer across body mass index groups.
    Holm JB; Baggesen E; Cronin-Fenton D; Frystyk J; Bruun JM; Christiansen P; Borgquist S
    Sci Rep; 2024 Jun; 14(1):14486. PubMed ID: 38914635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediagnostic serum inflammatory markers in relation to breast cancer risk, severity at diagnosis and survival in breast cancer patients.
    Wulaningsih W; Holmberg L; Garmo H; Malmstrom H; Lambe M; Hammar N; Walldius G; Jungner I; Van Hemelrijck M
    Carcinogenesis; 2015 Oct; 36(10):1121-8. PubMed ID: 26130675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Retrospective Propensity Score Matched Study of the Preoperative C-Reactive Protein to Albumin Ratio and Prognosis in Patients with Resectable Non-Metastatic Breast Cancer.
    Zhou L; Ma S; Balde AI; Han S; Cai Z; Li Z
    Med Sci Monit; 2019 Jun; 25():4342-4352. PubMed ID: 31182704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-reactive protein: a biomarker of survival in patients with localized upper tract urothelial carcinoma treated with radical nephroureterectomy.
    Obata J; Kikuchi E; Tanaka N; Matsumoto K; Hayakawa N; Ide H; Miyajima A; Nakagawa K; Oya M
    Urol Oncol; 2013 Nov; 31(8):1725-30. PubMed ID: 23141922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy.
    Thurner EM; Krenn-Pilko S; Langsenlehner U; Stojakovic T; Pichler M; Gerger A; Kapp KS; Langsenlehner T
    Eur J Cancer; 2015 Mar; 51(5):610-9. PubMed ID: 25618827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-reactive protein level on admission and time to and cause of death in patients hospitalized for acute heart failure.
    Minami Y; Kajimoto K; Sato N; Hagiwara N; Takano T;
    Eur Heart J Qual Care Clin Outcomes; 2017 Apr; 3(2):148-156. PubMed ID: 28927169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer.
    Caan BJ; Kwan ML; Hartzell G; Castillo A; Slattery ML; Sternfeld B; Weltzien E
    Cancer Causes Control; 2008 Dec; 19(10):1319-28. PubMed ID: 18752034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-diagnostic C-reactive protein and albumin predict survival in Chinese patients with non-small cell lung cancer: a prospective cohort study.
    Yang JR; Xu JY; Chen GC; Yu N; Yang J; Zeng DX; Gu MJ; Li DP; Zhang YS; Qin LQ
    Sci Rep; 2019 May; 9(1):8143. PubMed ID: 31148582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory biomarkers and risk of cancer in 84,000 individuals from the general population.
    Allin KH; Bojesen SE; Nordestgaard BG
    Int J Cancer; 2016 Oct; 139(7):1493-500. PubMed ID: 27194008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of time to death after distant recurrence in breast cancer patients.
    Sopik V; Sun P; Narod SA
    Breast Cancer Res Treat; 2019 Jan; 173(2):465-474. PubMed ID: 30328050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Serum Level of Vitamin D at Diagnosis With Breast Cancer Survival: A Case-Cohort Analysis in the Pathways Study.
    Yao S; Kwan ML; Ergas IJ; Roh JM; Cheng TD; Hong CC; McCann SE; Tang L; Davis W; Liu S; Quesenberry CP; Lee MM; Ambrosone CB; Kushi LH
    JAMA Oncol; 2017 Mar; 3(3):351-357. PubMed ID: 27832250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
    Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
    Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
    Regan MM; Neven P; Giobbie-Hurder A; Goldhirsch A; Ejlertsen B; Mauriac L; Forbes JF; Smith I; Láng I; Wardley A; Rabaglio M; Price KN; Gelber RD; Coates AS; Thürlimann B; ;
    Lancet Oncol; 2011 Nov; 12(12):1101-8. PubMed ID: 22018631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective evaluation of C-reactive protein, smoking and lung cancer death in the Third National Health and Nutrition Examination Survey.
    Bittoni MA; Focht BC; Clinton SK; Buckworth J; Harris RE
    Int J Oncol; 2015 Oct; 47(4):1537-44. PubMed ID: 26323323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postdiagnosis C-reactive protein and breast cancer survivorship: findings from the WHEL study.
    Villaseñor A; Flatt SW; Marinac C; Natarajan L; Pierce JP; Patterson RE
    Cancer Epidemiol Biomarkers Prev; 2014 Jan; 23(1):189-99. PubMed ID: 24220913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma C-reactive protein, genetic risk score, and risk of common cancers in the Atherosclerosis Risk in Communities study.
    Prizment AE; Folsom AR; Dreyfus J; Anderson KE; Visvanathan K; Joshu CE; Platz EA; Pankow JS
    Cancer Causes Control; 2013 Dec; 24(12):2077-87. PubMed ID: 24036889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.